ADAP News and Press, Adaptimmune Therapeutics plc From 05/14/20

Adaptimmune (NASDAQ: ADAP ): Q1 GAAP EPS of -$0.04 beats by $0.21 . More news on: Adaptimmune Therapeutics plc, Earnings news and commentary, Healthcare stocks news, Read more ...

- Upfront payment of $50m received from Astellas and approximately $90m offering completed -             - Financial guidance confirmed: funded into 2H 2021 - - Orphan Drug Designation positive opinion for ADP-A2M4 in the EU a...

CymaBay Therapeutics (NASDAQ: CBAY ) +147%  on upgrades  and Q1 results . More news on: CymaBay Therapeutics, Inc., Novavax, Inc., NanoViricides, Inc., News on the U.S. economy Read more ...

- Edited stem-cell derived T-cells can kill MAGE-A4 + cancer targets in vitro - - T-cell receptor expression edited in to stem cells - a milestone to build cell banks for clinical use - PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 12, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Ther...

- The Company will also present updated data at three Congresses - PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 29, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results for Q1 2020, before ...

The EMA's Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion for Orphan Drug Designation (ODD) for Adaptimmune Therapeutics' (NASDAQ: ADAP ) ADP-A2M4 for the treatment of soft tissue sarcomas. More news on: Adaptimmune Therapeutics plc, Healthcare stocks news, ...

PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 28, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, announced that the European Medicine Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a posi...

Adaptimmune Therapeutics Inc. (NASDAQ: ADAP) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We initiate shares of ADAP with a Neutral and a $3 price target. We see the efforts to develop a TCR-based treatment for solid tumors a...

Adaptimmune (NASDAQ: ADAP ) initiated with Neutral rating and $3 (17% downside risk) price target at Mizuho Securities. More news on: Adaptimmune Therapeutics plc, Autolus Therapeutics plc, Atreca, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Penny stocks, defined as equities that trade at less than $5 a share, are rarely worth the risk. Companies with extremely low share prices tend to have weak balance sheets, an absurdly high number of outstanding shares, few institutional investors, sky-high levels of interest from short-sellers,...